Securities in F&O Ban: PVR Inox, RBL Bank, Granules India and Manappuram Finance shares were banned from F&O trading on 10 December 2024. Stocks to Watch: Metropolis Healthcare's board approved the acquisition of 100% stake in Core Diagnostics for total consideration of Rs 246.8 crore. This strategic acquisition will enhance Metropolis' capabilities in advanced cancer testing, while deepening its presence in Northern and Eastern India and driving market share expansion in the specialized segment across the country. Bharat Electronics has received additional orders worth Rs 634 crore, including maintenance of the Aakash missile system, Telescopic sights for guns, communication equipment, jammers, electronic voting machines , test stations, spares and services. With these orders, the company has now accumulated a total of Rs 8,828 crore in orders for the current financial year. NHPC's board will meet on 12 December 2024 to consider a revised borrowing plant for raising debt during FY25, including raising funds through issuance of bonds upto Rs 2,600 crore in one or more tranches via private placement as part of the borrowingplany for FY25. JSW Steel has reported consolidated crude steel production for November at 23.23 lakh tonnes, up 5% compared to the year-ago period. India operations' production was higher by7% YoY, with capacity utilization for November at 94% for India Operations. GE Vernova T&D India has received an order worth Rs 400 crore from Sterlite Power fro the supply and supervision of 765KV power transmission and reactors for the khawda project. Lemon Tree Hotel has signed a License Agreement for a Lemon Tree Resort in Mirik, West Bengal. The property will be managed by the company's subsidiary, Carnation Hotels, and is expected to open in FY28. Isgec Heavy Engineering's non material subsidiary, Isgec Investments Pte Singapore has entered into sale and purchase agreement with Triumph Excel to sell its entire shareholding in its wholly owned subsidiary, Bioeq Energy Holdings One, Cayman Islands, for $10 million (Rs 84.5 crore).Powered by Capital Market - Live

The Board of Metropolis Healthcare at its meeting held on 09 December 2024 has approved the acquisition of the 100% stake in Core Diagnostics, India, (Core Diagnostics) from its existing shareholder, Core Diagnostics (Mauritius) for a total purchase consideration of Rs 246.83 crore to be discharged partly by cash and partly by way of preferential issue and allotment of equity shares of the Company (by way of share swap) subject to approval of the shareholders of the Company. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the Company. Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 9 December 2024Powered by Capital Market - Live

Revenue from operations grew 13.38% YoY to Rs 349.79 crore in the quarter ended 30 September 2024. Profit before tax jumped 27.62% to Rs 61.40 crore in Q2 FY25 as compared to Rs 48.11 crore recorded in the same quarter last year. EBITDA stood at Rs 91.5 crore, registering the growth of 22.2% as compared with Rs 74.9 crore posted in corresponding quarter last year. EBITDA margin improved to 26.2% in Q2 FY25 as against 24.3% in Q2 FY24. Consistent performance driven by sustained growth in Patient Volumes and Test Volumes, which stood at 7% and 8%, respectively for the quarter. Increase in Revenue Per Patient by 6%. The company reported strong year-on-year growth in its B2C revenue, which increased by 21% in Q2 FY25. B2B revenue also saw a robust growth of 13% YoY in Q2 FY25, marking the second consecutive quarter of double-digit growth. Additionally, TruHealth revenue grew by 23% YoY, while Specialty revenue rose by 16% YoY. On half year basis, the company's consolidated net profit surged 31.47% YoY to Rs 84.47 crore in H1 FY24 as compared to Rs 64.25 crore recorded in H1 FY25. Revenue from operations increased 13.24 YoY to Rs 663.14 in H1 FY25. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, 'We are delighted to share that Q2 FY25 has been a successful quarter, marked by a significant increase in revenue, driven by strong profit after tax (PAT) growth and solid execution from our management team. As we move forward, we will remain focused on advancing our testing capabilities to maintain our differentiated position in the market and to support sustainable long-term growth. Our consistent performance reflects our ability to increase patient volumes while maintaining robust growth trajectories in both B2C and B2B segments. With a solid pipeline of future initiatives, including potential mergers and acquisitions, we see a long growth runway ahead in a normalized competitive landscape and are wellpositioned to capitalize on these opportunities, ensuring long-term value creation for our shareholders.' Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, 'We have consistently achieved substantial growth, with revenue increasing by 13.4% and EBITDA rising by 22.2% year-on-year. This strong performance has been fuelled by a 21% YoY growth in B2C revenue, along with expansion in Tier 3 cities and an improvement in our average revenue per patient. Key growth areas, including our Specialty and TruHealth segments, have also contributed significantly. As we continue to broaden our footprint through our extensive network and valued partnerships, this strategic approach strengthens our position in a competitive landscape and paves the way for sustainable, long-term growth.' Meanwhile, the company's board has approved the appointment of Aditya Shinde as Interim Chief Financial Officer and Key Managerial Personnel, effective 11 November 2024. Metropolis Healthcare is a diagnostics company, with presence in 23 states & 601 towns. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 202 labs, 4,336 collection centres and over 10,000 touch points. Shares of Metropolis Healthcare added 0.12% to Rs 2,115.20 on Friday, 8 November 2024. Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 31.23% to Rs 46.52 crore in the quarter ended September 2024 as against Rs 35.45 crore during the previous quarter ended September 2023. Sales rose 13.38% to Rs 349.79 crore in the quarter ended September 2024 as against Rs 308.50 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales349.79308.50 13 OPM %25.7024.25 - PBDT88.2170.35 25 PBT61.4048.11 28 NP46.5235.45 31 Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

Metropolis Healthcare is a diagnostics company, with presence in 23 states & 601 towns. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 199 labs, 4,150 collection centres and over 10,000 touch points. The company's consolidated net profit increased 7.9% to Rs 36.1 crore in Q1 FY25 as compared with Rs 33.5 crore in Q1 FY24. Revenue from operations increased 17.7% to Rs 331 crore in Q1 FY25, compared to Rs 282.5 crore in Q1 FY24. The scrip rose 0.70% to settle at Rs 2,273.05 on Friday, 11 October 2024. Powered by Capital Market - Live

Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits. B2C revenues jumped around 20% YoY during the period under review, on account of industry-leading testing capabilities and strong brand appeal among end consumers. The company has been able to deliver strong results in Q2FY25 driven by a combination of increased volumes, product mix change and realizations benefits. Continued momentum from its Truhealth packages, along with successful upselling of bundled packages, led to higher test per patient, contributing to overall revenue growth. The company has added 6 labs and 120 centers in Q2FY25 and increased the presence to a total of approximately 700 towns in Q2FY25 compared to approximately 650 towns in FY24. Margins for Q2FY25 have expanded on a sequential basis in line with commentary provided earlier. The Company continues to see a gradual uptick in margins on account of operating leverage, cost optimization and growing contribution from its ongoing network expansion, it added. The company said that it is debt free & having cash reserves of approximately Rs 180 crore as on 30 September 2024. Metropolis Healthcare is a diagnostics company, with presence in 23 states & 601 towns. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 199 labs, 4,150 collection centres and over 10,000 touch points. The scrip fell 0.87% to settle at Rs 2,215 on the BSE.Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 31.77% to Rs 37.95 crore in the quarter ended June 2024 as against Rs 28.80 crore during the previous quarter ended June 2023. Sales rose 13.09% to Rs 313.36 crore in the quarter ended June 2024 as against Rs 277.09 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales313.36277.09 13 OPM %25.1522.71 - PBDT76.6260.01 28 PBT51.0839.19 30 NP37.9528.80 32 Powered by Capital Market - Live